Johnson & Johnson begins final stage trial of COVID-19 vaccine
NEW YORK — This week Johnson & Johnson said that it had begun its large-scale, pivotal, multi-country Phase-3 trial for its COVID-19 vaccine candidate. The company said it expects the first batches of the COVID-19 vaccine, JNJ-78436735, to be available for emergency use authorization in early next year, if proven to be safe and effective.